These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20587645)

  • 41. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase.
    Chilukuri N; Sun W; Naik RS; Parikh K; Tang L; Doctor BP; Saxena A
    Chem Biol Interact; 2008 Sep; 175(1-3):255-60. PubMed ID: 18603232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
    Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of polymer concentration on camouflaging of pancreatic islets with mPEG-succinimidyl carbonate.
    Lazarjani HA; Vasheghani-Farahani E; Barani L; Hashemi-Najafabadi S; Shojaosadati SA; Zahediasl S; Tairahi T; Atyabi F
    Artif Cells Blood Substit Immobil Biotechnol; 2010 Oct; 38(5):250-8. PubMed ID: 20486872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Manipulation of in vitro angiogenesis using peptide-coated gold nanoparticles.
    Bartczak D; Muskens OL; Sanchez-Elsner T; Kanaras AG; Millar TM
    ACS Nano; 2013 Jun; 7(6):5628-36. PubMed ID: 23713973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue.
    Hee Na D; Seok Youn Y; Bok Lee I; Ji Park E; Jeon Park C; Choon Lee K
    Pharm Dev Technol; 2006; 11(4):513-9. PubMed ID: 17101522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation.
    Hong S; Haibing H; Jialiang H; Xiaojuan Z; Jingjing W; Wenjing W; Caihui N; Hanmei X
    J Mater Chem B; 2014 Feb; 2(7):800-813. PubMed ID: 32261312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cobalt(III)-induced hexamerization of PEGylated insulin.
    Lim SI; Jang MH; Kim DJ; Bae SM; Kwon SC
    Int J Biol Macromol; 2011 Nov; 49(4):832-7. PubMed ID: 21835194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biophysical and biological characterization of PEGylated recombinant human endostatin.
    Guo L; Xu B; Zhou D; Chang G; Fu Y; Liu L; Luo Y
    Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):920-927. PubMed ID: 31278773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RGD-modified angiogenesis inhibitor HM-3 dose: dual function during cancer treatment.
    Xu H; Pan L; Ren Y; Yang Y; Huang X; Liu Z
    Bioconjug Chem; 2011 Jul; 22(7):1386-93. PubMed ID: 21668003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of two different polyethylene glycol (PEG) derivatives on the immunological response of PEG grafted pancreatic islets.
    Aghajani-Lazarjani H; Vasheghani-Farahani E; Shojaosadati SA; Hashemi-Najafabadi S; Zahediasl S; Tiraihi T; Atyabi F
    J Artif Organs; 2010 Dec; 13(4):218-24. PubMed ID: 21127930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
    Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    Br J Cancer; 1996 Oct; 74(7):1090-5. PubMed ID: 8855980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: Glycol-split heparin-endostatin2 (GSHP-ES2).
    Sun F; Wang Z; Yang Z; Li Y; Cui H; Liu C; Gao D; Wang F; Tan H
    Carbohydr Polym; 2019 Mar; 207():79-90. PubMed ID: 30600066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stability Characterization of the Novel Anti-Cancer HM-10/10 HDL-Mimetic Peptide.
    Dempsey MP; Andersen KE; Wells BM; Taylor MA; Cashman CL; Conrad LB; Kearney CA; Conklin MB; Via ER; Doe EM; Komirisetty R; Dearborn S; Reddy ST; Farias-Eisner R
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polyethylene Glycol 20k. Does It Fluoresce?
    Laatsch BF; Brandt M; Finke B; Fossum CJ; Wackett MJ; Lowater HR; Narkiewicz-Jodko A; Le CN; Yang T; Glogowski EM; Bailey-Hartsel SC; Bhattacharyya S; Hati S
    ACS Omega; 2023 Apr; 8(15):14208-14218. PubMed ID: 37180871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities.
    Li T; Zhang HZ; Ge GF; Yue ZR; Wang RY; Zhang Q; Gu Y; Song MJ; Li WB; Ma MZ; Wang MZ; Yang H; Li Y; Li HY
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy.
    Li W; Xue J; Xu H
    Int J Nanomedicine; 2019; 14():1011-1026. PubMed ID: 30799919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis.
    Huang R; Li J; Wang Y; Zhang L; Ma X; Wang H; Li W; Cao X; Xu H; Hu J
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201867
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.